Argus reiterated their buy rating on shares of Bristol-Myers Squibb (NYSE:BMY) in a research note issued to investors on Wednesday morning. The brokerage currently has a $66.43 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $75.00.
BMY has been the subject of a number of other reports. Vetr cut shares of Bristol-Myers Squibb from a buy rating to a hold rating and set a $59.70 target price for the company. in a report on Friday, December 22nd. BMO Capital Markets set a $51.00 target price on shares of Bristol-Myers Squibb and gave the company a sell rating in a report on Wednesday, February 14th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a hold rating to a sell rating in a report on Monday, January 29th. TheStreet cut shares of Bristol-Myers Squibb from a b rating to a c+ rating in a report on Thursday, March 8th. Finally, Credit Suisse Group set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a hold rating in a report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $66.79.
Shares of BMY stock opened at $66.10 on Wednesday. Bristol-Myers Squibb has a 1-year low of $51.56 and a 1-year high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The company has a market cap of $108,452.49, a PE ratio of 112.03, a PEG ratio of 2.03 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb will post 3.22 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.42%. Bristol-Myers Squibb’s payout ratio is currently 271.19%.
Institutional investors and hedge funds have recently modified their holdings of the business. Delphi Private Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $108,000. Atlantic Trust LLC acquired a new position in Bristol-Myers Squibb during the second quarter worth about $111,000. Massey Quick Simon & CO. LLC grew its position in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. NuWave Investment Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $119,000. Finally, Horan Capital Advisors LLC. acquired a new position in Bristol-Myers Squibb during the third quarter worth about $122,000. Institutional investors own 71.49% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/22/bristol-myers-squibbs-bmy-buy-rating-reaffirmed-at-argus.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.